Boceprevir in End Stage Renal Disease (ESRD)
- Status
- WITHDRAWN
- Phase
- NA
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
- Status
- COMPLETED
- Phase
- PHASE1
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
- Status
- COMPLETED
- Phase
- PHASE3
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)
- Status
- COMPLETED
- Phase
- PHASE3
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)
- Status
- COMPLETED
- Phase
- PHASE2
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
- Status
- COMPLETED
- Phase
- PHASE3
Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
- Status
- COMPLETED
- Phase
- PHASE4
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)
- Status
- COMPLETED
- Phase
- PHASE1
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE1
A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)
- Status
- TERMINATED
- Phase
- PHASE1
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
- Status
- COMPLETED
- Phase
- PHASE1
Spanish Registry of Systemic Treatments in Psoriasis
- Status
- RECRUITING
- Phase
- N/A
Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection
- Status
- WITHDRAWN
- Phase
- NA
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Status
- COMPLETED
- Phase
- PHASE3